Testosterone Reliably Causes Acne. The Counselling Almost Never Mentions It.

The number nobody quotes at the first appointment

Anyone starting testosterone gets a briefing. Haematocrit will be checked. Lipids will be discussed. Blood pressure, prostate markers where relevant, injection technique, what to do if the level runs high. It is a reasonably thorough conversation.

And then, in most cases, nothing about the skin — despite the skin being the organ that will change first, change visibly, and change in a way that leaves permanent marks if it is handled badly.

The numbers are not ambiguous. In a cohort of 988 transgender men receiving masculinising hormone therapy, acne prevalence went from 6.3% before therapy to 31.1% over a mean of 3.4 years on it. Incidence was 19.0% at one year and 25.1% at two, and the peak arrived early: 11.8% in the first six months alone. A separate prospective multicentre study following 323 people through their first three years found moderate-to-severe acne rising from 11.8% to 39.1% after a single year.

That second figure is the one worth sitting with. It is not measuring "some spots." It is measuring the grade of disease that scars.

The same study identified who is most exposed: a BMI above 25, starting therapy between 18 and 25, serum testosterone at or above the target range rather than below it, and — most usefully — having any acne at baseline at all, which nearly doubled the risk. Those are all knowable before the first injection. None of them are routinely used to trigger a dermatological conversation.

Why it starts on the back

The mechanism is short. Sebaceous glands are androgen target tissue; raise circulating androgen and sebocytes enlarge, lipid synthesis climbs, and the follicular environment shifts in favour of Cutibacterium acnes. This is the same axis that produces adolescent acne, restarted in an adult body at an adult dose.

What makes androgen-driven acne behave differently from ordinary adult acne is where the glands are. Sebaceous gland density is highest on the face, but the upper back, shoulders and chest carry large glands in dense fields, and those fields respond to systemic androgen just as briskly as the face does. The difference is that the back is covered by a shirt, rubbed by fabric and straps, sweated on during training, and — the recurring theme in men's skin — not visible to its owner.

So the sequence is usually: the face gets oilier and slightly congested, which registers as unremarkable; meanwhile the shoulders and upper back develop inflammatory papules and nodules that nobody notices for weeks. By the time it is obvious, the lesions are deeper and older than facial ones would have been at first notice, and deep truncal lesions are exactly the ones that leave ↗the kind of scarring that needs its own therapy pathway.

That delay is the whole argument for treating pre-emptively rather than reactively. Nothing about the biology is surprising. The surprise is always the timing of noticing.

The plan to start on day one, not month four

The genuinely useful move is to build the routine at the same time as the first dose, on the assumption that it will be needed, and to treat being wrong as a good outcome rather than wasted effort.

Start with a wash that carries ↗benzoyl peroxide and use it on the back, shoulders and chest rather than only the face. PanOxyl Acne Foaming Wash is the standard workhorse here — used in the shower with a short contact time, then rinsed. If it proves too drying, CeraVe Acne Foaming Cream Cleanser delivers the same active in a lower-strength, ceramide-buffered base. Benzoyl peroxide is worth prioritising over an antibiotic-first approach because bacterial resistance does not develop against it, which matters over a course of treatment measured in years rather than weeks. It bleaches fabric, so dark towels and old shirts are part of the plan.

Add ↗adapalene as the leave-on. Differin Adapalene Gel is the face version and is available without a prescription in the US. The genuine problem is reach: a gel tube cannot be applied evenly to your own upper back. Both Differin Acne-Clearing Body Spray and PanOxyl Acne Banishing Body Spray exist specifically to solve that geometry, and a spray you can actually deploy nightly beats a gel you apply badly twice a week.

Then moisturise, because the failure mode of this routine is abandoning it. Benzoyl peroxide plus a retinoid is a drying combination and the first two weeks are the hardest; an oil-free option such as PanOxyl PM Acne Clearing Oil-Free Moisturizer keeps the routine survivable. Expect the retinoid to make things look slightly worse before better — ↗what to expect after starting testosterone covers the distinction between that adjustment and a genuine flare, and the Purging or Breakout tool walks the same decision if you are unsure which one you are looking at.

When it stops being a skincare problem

There is a threshold past which topicals are not the answer, and androgen-driven acne crosses it more often than ordinary adult acne does.

The honest markers are these: nodules rather than papules, lesions that are painful to press, anything that lasts more than a few weeks in one spot, marks that are still visible months after the lesion cleared, or a distribution spreading down the back rather than staying on the shoulders. Any of those is a dermatology referral, not a stronger cleanser. Current guideline-level care escalates through combination topicals to oral therapy — and in appropriate cases to isotretinoin, which is the only intervention that reliably shrinks sebaceous glands rather than managing their output. The Acne Severity tool will give you a defensible grade to bring to that appointment, and the Derm Visit Prep tool turns "my skin got worse" into the specifics a fifteen-minute consultation actually needs.

Two things about the isotretinoin conversation are worth knowing in advance, because they change how the first appointment should go.

The first is a real hazard rather than a hypothetical. Starting isotretinoin at a full dose into severe nodular acne can precipitate acne fulminans — an explosive, ulcerating, sometimes systemic worsening. The published expert consensus on managing acne fulminans and its variants is explicit that the way to avoid this is a low starting dose with oral corticosteroid cover, escalating slowly. If a clinician proposes going straight to a standard dose on a back full of nodules, that is a reasonable thing to ask about.

The second matters for anyone on testosterone who can still become pregnant. Testosterone therapy is not contraception and does not reliably suppress ovulation, and isotretinoin is a potent teratogen with a mandatory pregnancy-prevention programme attached. Amenorrhoea on testosterone is not evidence of infertility. This is a point where the endocrinology and the dermatology need to be in the same conversation rather than in two clinics that never speak.

The gym version is a different disease

Everything above describes physiologic or near-physiologic dosing. Supraphysiologic androgen use is a separate clinical picture, and it deserves describing without moralising, because moralising is precisely why the people affected do not disclose it and therefore do not get treated.

Acne occurs in roughly half of anabolic-androgenic steroid users, concentrated in men aged eighteen to twenty-six, and it is one of the more reliable external indicators of use. Both acne conglobata and acne fulminans are documented outcomes — the severe, nodular, tunnelling, sometimes ulcerative forms rather than the ordinary inflammatory kind. It appears fast, it favours the same truncal fields, and it does not respond to the routine described above because the driver is an order of magnitude larger.

The practical points are unglamorous. Disclosure to the treating clinician changes the plan materially, and dermatologists are not in the business of reporting anyone. Severity here is a reason for early systemic treatment rather than a longer topical trial. And the sequencing hazard above is more relevant, not less: this is exactly the population in which an aggressive isotretinoin start has precipitated fulminans in the published cases. ↗Our cystic acne shortlist is a stopgap for the mild end of this, and explicitly not a substitute for the referral at the severe end.

What the first three months should look like

Compressed into something you can act on the week you start.

Photograph your back before the first dose. Same light, arms down, one shot. It sounds excessive and it is the single most useful thing on this list, because androgen acne is a change-over-time problem and neither you nor a clinician can grade it from memory. Repeat monthly. If you are already using a tracker for anything else, this belongs in it.

Start the wash and the leave-on in week one rather than waiting for a reason. If nothing happens, you have spent a few weeks of mild dryness on insurance against the outcome that scars.

Expect the peak between roughly month three and month twelve, with the sharpest incidence in the first six months. Knowing that stops two errors: panicking at week six and concluding the therapy is wrong for you, and assuming at month two that you got away with it.

Raise it at your next hormone review rather than waiting for a separate dermatology appointment, because dose and level are part of the picture — the risk data associates concentrations at or above the target range with more severe disease, which is a legitimate thing to discuss alongside the rest of your bloodwork. ↗The acne pathway lays out the full escalation ladder so you can see where you actually sit on it, and ↗the scarring question covers what is treatable later and what is not — which, more than anything else here, is the argument for moving early.